1. CD36 promotes tubular ferroptosis by regulating the ubiquitination of FSP1 in acute kidney injury
- Author
-
Yixin Ma, Lili Huang, Zheng Zhang, Pengfei Yang, Qingsong Chen, Xujia Zeng, Fangyan Tan, Chunxia Wang, Xiongzhong Ruan, and Xiaohui Liao
- Subjects
Acute kidney injury ,CD36 ,Ferroptosis ,FSP1 ,Ubiquitin-dependent degradation ,Medicine (General) ,R5-920 ,Genetics ,QH426-470 - Abstract
Reactive oxidative species (ROS) production-driven ferroptosis plays a role in acute kidney injury (AKI). However, its exact molecular mechanism is poorly understood. Scavenger receptor CD36 has important roles in oxidizing lipids, lipid accumulation, metabolic syndrome, and insulin resistance in chronic kidney disease, but its roles remain unexplored in AKI. The present study investigated the role and mechanism of CD36 in regulating proximal tubular cell ferroptosis and AKI. The expression of CD36 was found to be significantly up-regulated in AKI renal tissues and correlated with renal function, which might serve as an independent biomarker for AKI patients. Moreover, in adult mice subjected to AKI, deletion of CD36 (CD36−/−) induced tubular cell ROS accumulation, ferroptosis activation, and renal injury. Mechanistically, combining LC-MS/MS, co-IP, and ubiquitination analyses revealed that CD36 could specifically bind to ferroptosis suppressor protein 1 (FSP1) and regulate its ubiquitination at sites K16 and K24, leading to FSP1 degradation and progression of ferroptosis in AKI. The present results emphasize a novel mechanism of CD36 in cisplatin-induced AKI. The discovery of the special CD36 roles in promoting ferroptosis and AKI development by regulating the ubiquitination of FSP1 in proximal tubular cells may be potential therapeutic targets for AKI. Moreover, CD36 may play a key role in the progression of AKI. Therefore, targeting CD36 may provide a promising treatment option for AKI.
- Published
- 2024
- Full Text
- View/download PDF